CA3242970A1 - ANTIBODY-DRUG CONJUGATE TARGETING CLAUDINE 18.2 - Google Patents
ANTIBODY-DRUG CONJUGATE TARGETING CLAUDINE 18.2Info
- Publication number
- CA3242970A1 CA3242970A1 CA3242970A CA3242970A CA3242970A1 CA 3242970 A1 CA3242970 A1 CA 3242970A1 CA 3242970 A CA3242970 A CA 3242970A CA 3242970 A CA3242970 A CA 3242970A CA 3242970 A1 CA3242970 A1 CA 3242970A1
- Authority
- CA
- Canada
- Prior art keywords
- antibody
- drug conjugate
- conjugate targeting
- targeting
- adc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111551337.8 | 2021-12-17 | ||
| CN202111551337 | 2021-12-17 | ||
| PCT/CN2022/139637 WO2023109953A1 (zh) | 2021-12-17 | 2022-12-16 | 靶向Claudin18.2的抗体-药物偶联物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3242970A1 true CA3242970A1 (en) | 2023-06-22 |
Family
ID=86774867
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3242970A Pending CA3242970A1 (en) | 2021-12-17 | 2022-12-16 | ANTIBODY-DRUG CONJUGATE TARGETING CLAUDINE 18.2 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20250073347A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4450521A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7796230B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240133715A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119173534A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022416272A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3242970A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TWI869741B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023109953A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022416272A1 (en) * | 2021-12-17 | 2024-07-18 | Fortvita Biologics (Singapore) Pte. Ltd. | Antibody-drug conjugate targeting claudin18.2 |
| EP4623936A1 (en) * | 2022-11-22 | 2025-10-01 | Keymed Biosciences (Chengdu) Co., Ltd. | Fused ring compound, conjugate thereof and use thereof |
| CN119591708A (zh) * | 2023-09-08 | 2025-03-11 | 成都临界点生物科技有限公司 | 抗Claudin18.2人源化单域抗体 |
| WO2025077815A1 (zh) * | 2023-10-11 | 2025-04-17 | 福佑泰生物制药(新加坡)公司 | 靶向Claudin18.2的抗体-药物偶联物联合治疗癌症的方法 |
| TW202532100A (zh) * | 2023-12-22 | 2025-08-16 | 大陸商信達生物製藥(蘇州)有限公司 | 靶向b7h3和egfr的雙特異性抗體-藥物偶聯物及其應用 |
| TW202545991A (zh) * | 2024-01-12 | 2025-12-01 | 大陸商信達生物製藥(蘇州)有限公司 | 抗cd28抗體及其用途 |
| WO2026052046A1 (zh) * | 2024-09-06 | 2026-03-12 | 荣昌生物制药(烟台)股份有限公司 | 抗Claudin18.2抗体药物偶联物用于治疗胃癌和/或胃食管结合部腺癌的用途 |
| CN119345386B (zh) * | 2024-10-25 | 2025-12-09 | 华润生物医药有限公司 | 靶向Claudin18.2的抗体药物耦联物及其用途 |
| WO2026120140A1 (en) | 2024-12-05 | 2026-06-11 | Medizinische Universität Wien | Hydroxy cinnamic acid derivatives |
| WO2026124417A1 (en) * | 2024-12-09 | 2026-06-18 | Lepu Biopharma Co., Ltd. | Anti-cdh17 antibody-drug conjugates and uses thereof |
| CN121130103A (zh) * | 2025-11-05 | 2025-12-16 | 上海以岭药业有限公司 | 靶向cldn 18.2的抗体药物偶联物及其应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9580511B2 (en) * | 2013-03-11 | 2017-02-28 | Genzyme Corporation | Site-specific antibody-drug conjugation through glycoengineering |
| CN106589127A (zh) * | 2015-10-16 | 2017-04-26 | 钜川生物医药 | 一种pcsk9抗体及其制备方法和应用 |
| CA3177215C (en) * | 2017-09-29 | 2026-06-09 | Daiichi Sankyo Company, Limited | Antibody-pyrrolobenzodiazepine derivative conjugate |
| EP3808376A4 (en) * | 2018-06-17 | 2021-09-01 | L&L Biopharma Co., Ltd. | CLDN18.2 ANTIBODY, BISPECIFIC ANTIBODY, ADC AND CAR, AND APPLICATIONS THEREOF |
| AU2019414968A1 (en) * | 2018-12-27 | 2021-08-12 | Gigagen, Inc. | Anti-PD-1 binding proteins and methods of use thereof |
| KR20210109520A (ko) * | 2018-12-28 | 2021-09-06 | 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 | 항체 및 이의 용도 |
| EP3950061A4 (en) * | 2019-03-25 | 2022-11-16 | Daiichi Sankyo Company, Limited | ANTIBODY PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE |
| CN117731798A (zh) | 2019-06-28 | 2024-03-22 | 泰州复旦张江药业有限公司 | 抗体偶联药物、其中间体、制备方法及应用 |
| CA3147122A1 (en) * | 2019-07-12 | 2021-01-21 | Futuregen Biopharmaceutical (Beijing) Co., Ltd. | Cldn18.2 antibody and use thereof |
| CN112707965A (zh) * | 2019-09-30 | 2021-04-27 | 和铂医药(苏州)有限公司 | 靶向cldn18.2的抗体及其制备方法和应用 |
| AU2020402006A1 (en) | 2019-12-12 | 2022-07-07 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-claudin antibody-drug conjugate and pharmaceutical use thereof |
| CA3178855A1 (en) * | 2020-06-19 | 2021-12-23 | Innovent Biologics (Suzhou) Co., Ltd. | Anti-claudin18.2 antibody and use thereof |
| JP7904824B2 (ja) | 2020-09-15 | 2026-08-13 | シンアフィックス ビー.ブイ. | 抗体-エクサテカンコンジュゲート |
| US20240293457A1 (en) * | 2020-12-25 | 2024-09-05 | Innovent Biologics (Suzhou) Co., Ltd. | Claudin18.2 chimeric antigen receptor and use thereof |
| AU2022416272A1 (en) * | 2021-12-17 | 2024-07-18 | Fortvita Biologics (Singapore) Pte. Ltd. | Antibody-drug conjugate targeting claudin18.2 |
-
2022
- 2022-12-16 AU AU2022416272A patent/AU2022416272A1/en active Pending
- 2022-12-16 US US18/719,023 patent/US20250073347A1/en active Pending
- 2022-12-16 TW TW111148546A patent/TWI869741B/zh active
- 2022-12-16 EP EP22906698.0A patent/EP4450521A1/en active Pending
- 2022-12-16 JP JP2024535848A patent/JP7796230B2/ja active Active
- 2022-12-16 CN CN202280083295.6A patent/CN119173534A/zh active Pending
- 2022-12-16 WO PCT/CN2022/139637 patent/WO2023109953A1/zh not_active Ceased
- 2022-12-16 CA CA3242970A patent/CA3242970A1/en active Pending
- 2022-12-16 KR KR1020247023670A patent/KR20240133715A/ko active Pending
-
2025
- 2025-10-31 US US19/376,098 patent/US20260216353A1/en active Pending
- 2025-12-22 JP JP2025271167A patent/JP2026053502A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240133715A (ko) | 2024-09-04 |
| EP4450521A1 (en) | 2024-10-23 |
| JP2026053502A (ja) | 2026-03-25 |
| JP2024546497A (ja) | 2024-12-24 |
| US20260216353A1 (en) | 2026-07-30 |
| TW202333798A (zh) | 2023-09-01 |
| CN119173534A (zh) | 2024-12-20 |
| AU2022416272A1 (en) | 2024-07-18 |
| US20250073347A1 (en) | 2025-03-06 |
| WO2023109953A9 (zh) | 2023-07-27 |
| WO2023109953A1 (zh) | 2023-06-22 |
| TWI869741B (zh) | 2025-01-11 |
| JP7796230B2 (ja) | 2026-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021550692A1 (en) | Conjugation linkers containing 2,3-diaminosuccinyl group | |
| EP4025257A4 (en) | ANTIBODY DRUG CONJUGATE WITH ANTIBODIES TO HUMAN ROR1 AND USE THEREOF | |
| EP4223316A3 (en) | Improved antibody-oligonucleotide conjugate | |
| WO2001026693A3 (en) | Manufacture of polyglutamate-therapeutic agent conjugates | |
| EP4332117A4 (en) | ANTI-NECTIN-4 ANTIBODIES AND ANTI-NECTIN-4 ANTIBODY-DRUG CONJUGATE AND MEDICAL USERS THEREOF | |
| WO2020236841A3 (en) | Antibody drug conjugates having linkers comprising hydrophilic groups | |
| GEP20063917B (en) | Pulmonary administration of chemically modified insulin | |
| EP2311488A3 (en) | Vaccine composition | |
| WO2001082899A3 (en) | Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites | |
| AU2003300835A1 (en) | Angle indexer for medical devices | |
| EP2266622A3 (en) | Prodrugs containing novel bio-cleavable linkers | |
| WO2007054364A3 (en) | Balloon catheter with elastic segment | |
| WO2006064453A3 (en) | Targeting agents for molecular imaging | |
| MX2023003448A (es) | Composicion farmaceutica que comprende conjugado de anticuerpo-farmaco y uso de la misma. | |
| WO2018124512A3 (ko) | 압타머-약물 콘쥬게이트 및 그 용도 | |
| MX2024010601A (es) | Conjugado anticuerpo-farmaco, composicion farmaceutica del mismo y uso del mismo. | |
| AU2001276689A1 (en) | Novel remedies for cancer | |
| WO2004111192A3 (en) | Targeted delivery to legumain-expressing cells | |
| CA3242972A1 (en) | Anti-ROR1 antibodies, anti-ROR1 antibody-drug combinations, and their medical uses | |
| WO2024197140A3 (en) | Dll3 antibody-drug conjugates and uses thereof | |
| WO2020087057A8 (en) | Macromolecular prodrug-based thermosensitive injectable gel as a novel drug delivery platform | |
| WO2002096367A3 (en) | Targeted multivalent macromolecules | |
| WO2004004639A3 (en) | A novel stable formulation | |
| WO2025054560A3 (en) | Antibody-drug conjugates | |
| WO2003082926A3 (en) | Antimicrobial polymer conjugates |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20240703 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P104 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR PRIORITY RECEIVED Effective date: 20240703 Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20240703 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W00-W00-W128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: INACTIVE: IPC ASSIGNED Effective date: 20240703 Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20240703 Free format text: ST27 STATUS EVENT CODE: A-1-1-W00-W00-W005 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: INACTIVE: FIRST IPC ASSIGNED Effective date: 20240703 Free format text: ST27 STATUS EVENT CODE: A-1-1-W00-W00-W128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ARCHIVED EVENT: IPC ASSIGNED Effective date: 20240703 Free format text: ST27 STATUS EVENT CODE: A-1-1-W00-W00-W005 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ARCHIVED EVENT: FIRST IPC ASSIGNED Effective date: 20240703 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P145 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - DEFECT(S) Effective date: 20240722 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241127 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241127 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241127 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250401 Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED Effective date: 20250401 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251201 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251201 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED Effective date: 20260501 Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260501 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REGISTER A DOCUMENT REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260504 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260601 |